Recent Updates
Recently added Catalysts
ECOR Positive Sentiment

electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026

Key Takeaway: electroCore, Inc. will announce its third-quarter financial results for 2026 on November 4. The results will be shared after market close, followed by a conference call at 4:30 PM EST. This event will allow management to review the results and address any investor questions.

Market Sentiment Analysis

POSITIVE FACTORS

  • electroCore will report Q3 financial results soon.
  • Management will host a conference call for investors.
  • The company focuses on innovative bioelectronic technologies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
GammaCore
Phase 2 · Chronic Cluster Headache

Full Press Release Details

ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026. Management will host a conference call and webcast at 4:30 PM EST that day to review the results and answer questions.
Participants may join by telephone or webcast using the details below.
Wednesday, November 4, 2026 at 4:30 pm EST Participant Dial-In: 877-407-8835 / +1 201-689-8779 Conference ID #: 13763480 Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=af6qsd3k
A replay of the webcast will be available in the Investors section of the Company’s website at investor.electrocore.com.
About electroCore, Inc. electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.

Contact: ECOR Investor Relations (973) 302-9253 investors@electrocore.com

Frequently Asked Questions

When will electroCore announce its Q3 2026 results?

electroCore will announce its Q3 2026 results on November 4, 2026.

What time is the conference call for Q3 results?

The conference call is scheduled for 4:30 PM EST on November 4, 2026.

How can I join the electroCore conference call?

Participants can join by telephone or via the provided webcast link.

What products does electroCore focus on?

electroCore focuses on bioelectronic technologies for chronic pain and wellness.

Last updated: Oct 29, 2026